Docetaxel (Taxotere®)

DRUG5 trials

Sponsors

Hoffmann-La Roche, H. Lee Moffitt Cancer Center and Research Institute, Sanofi, National University Hospital, Singapore

Conditions

Breast CancerCarcinomaNon Small Cell LungNon-Small Cell Lung CancerOvarian CancerSolid Tumors

Phase 1

Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle

CompletedNCT00703378

National University Hospital, SingaporeSolid Tumors

Start: 2006-05-31End: 2012-02-29Updated: 2012-03-28

Phase 2

A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

CompletedNCT00077857

Hoffmann-La RocheBreast Cancer

Start: 2003-07-31End: 2010-03-31Updated: 2013-05-10

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

CompletedNCT00231465

H. Lee Moffitt Cancer Center and Research InstituteNon-Small Cell Lung Cancer

Start: 2003-07-31End: 2012-08-31Updated: 2017-03-03

TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary

CompletedNCT00296816

SanofiOvarian Cancer

Start: 2006-03-31End: 2011-08-31Updated: 2012-08-23

Phase 3

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

CompletedNCT00532155

SanofiCarcinoma, Non Small Cell Lung

Start: 2007-09-30End: 2011-10-31Updated: 2025-09-10

Related Papers

Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study

Cancer Science2015-12-126 citations

A preclinical and clinical review of aflibercept for the management of cancer.

2012-01-2081 citations